New portfolio for imaging systems could reduce impact on patient care.
Institutions with Siemens Healthineers products can now select a service contract option that best matches their operational schedule, limiting the impact of routine maintenance on patient care activities.
With CentriCare – a new, patient-centric service contract portfolio – Siemens allows customers to select the most convenient time period for company personnel to address non-urgent service requests. Doing so addresses the issue of existing service contracts frequently overlapping with operational hours, the company said. It's a problem that can result in preventive maintenance infringing on patient care.
According to a press statement, CentriCare offers three flexible service plans – Signature, Benchmark, and Balance – that offer more system availability and uptime while limitng clinical disruption during time periods where machines are needed most for patient care.
“Customers have asked us to align with their priorities so that they can provide an optimal patient experience free of offline imaging systems and extended patient wait times. These customers also want to avoid related out-of-scope service expenses, such as overtime, spare parts, and expediated shipping charges,” said Michael Wendt, senior vice president of customer services at Siemens Healthineers, in the written statement. “The CentriCare service portfolio is a direct response to these customer requests.”
Each plan offers Protected Care Hours during which Siemens guarantees 100-percent uptime, according to the company statement. But, if service-hour interruptions do occur, the CentriCare Entrust Program offers per-hour credits that can be applied to current or future invoices for other Siemens products and services. Other CentriCare components can include single vendor point-of-contact, including dedicated VIP phone line or a clinical or technical concierge expert, to help with onboarding to service escalations and incident reporting.
Currently, CentriCare service contracts are available in certain parts of the United States, including the Northeast.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.